Correlation Between Elixinol Global and Canntab Therapeutics

Can any of the company-specific risk be diversified away by investing in both Elixinol Global and Canntab Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Elixinol Global and Canntab Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Elixinol Global and Canntab Therapeutics Limited, you can compare the effects of market volatilities on Elixinol Global and Canntab Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Elixinol Global with a short position of Canntab Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Elixinol Global and Canntab Therapeutics.

Diversification Opportunities for Elixinol Global and Canntab Therapeutics

0.0

Correlation Coefficient

Elixinol Global  Canntab Therapeutics

Pay attention - limited upside

The 3 months correlation between Elixinol and Canntab is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Elixinol Global and Canntab Therapeutics Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Canntab Therapeutics and Elixinol Global is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Elixinol Global are associated (or correlated) with Canntab Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Canntab Therapeutics has no effect on the direction of Elixinol Global i.e., Elixinol Global and Canntab Therapeutics go up and down completely randomly.

Pair Corralation between Elixinol Global and Canntab Therapeutics

Assuming the 90 days horizon Elixinol Global is expected to generate 2.99 times more return on investment than Canntab Therapeutics. However, Elixinol Global is 2.99 times more volatile than Canntab Therapeutics Limited. It trades about 0.15 of its potential returns per unit of risk. Canntab Therapeutics Limited is currently generating about 0.06 per unit of risk. If you would invest  0.65  in Elixinol Global on December 3, 2024 and sell it today you would earn a total of  1.35  from holding Elixinol Global or generate 207.69% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	98.79%
Values	Daily Returns

Elixinol Global  vs.  Canntab Therapeutics Limited

Elixinol Global

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Elixinol Global are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, Elixinol Global reported solid returns over the last few months and may actually be approaching a breakup point.

Canntab Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Canntab Therapeutics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental drivers, Canntab Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders.

Pair Trading with Elixinol Global and Canntab Therapeutics

The main advantage of trading using opposite Elixinol Global and Canntab Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Elixinol Global position performs unexpectedly, Canntab Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Canntab Therapeutics will offset losses from the drop in Canntab Therapeutics' long position.

The idea behind Elixinol Global and Canntab Therapeutics Limited pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.